Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.

ABSTRACT: Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004-2021), we identified patients with aRCC across the pre-ICI and ICI eras and stratified them into younger (<65 years) and older (≥65 years) groups. Survival analyses, including Kaplan-Meier curves and multivariate Cox regression models, were performed to assess overall survival (

SUBMITTER: Al-Danakh A 

PROVIDER: S-EPMC12695934 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature